Evidence map›Paper›PMID 42614585›Full record

Trial reportOpen forum infectious diseases2026

Single-dose Ceftriaxone Plus 7-Day Doxycycline Versus Single-dose Benzathine Penicillin G Plus 7-Day Doxycycline in the Treatment of Early Syphilis in People With HIV: a Pilot Randomized Noninferiority Trial.

Tzong-Yow Wu, Kuan-Yin Lin, Hsin-Yun Sun, Yu-Shan Huang, Wang-Da Liu, Aristine Cheng, Wang-Huei Sheng, Wen-Chun Liu, Li-Hsin Su, Yi-Ching Su and 1 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tzong-Yow WuDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.ORCID https://orcid.org/0009-0005-2825-8534
Kuan-Yin LinDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-6877-5345
Hsin-Yun SunDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0003-0074-7721
Yu-Shan HuangDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-9047-5709
Wang-Da LiuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Aristine ChengDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Wang-Huei ShengDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Wen-Chun LiuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Li-Hsin SuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Yi-Ching SuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Chien-Ching HungDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.ORCID https://orcid.org/0000-0001-7345-0836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Both ceftriaxone (CRO) and doxycycline demonstrate activity against Methods: In this pilot randomized clinical trial, eligible participants were randomized to receive CRO/Doxy or BPG/Doxy. Rapid plasma reagin (RPR) titers were determined at baseline and at weeks 4, 12, 24, 36 and 48. PCR assays were conducted at baseline and at week 4 to detect Results: From March 2023 to September 2024, 56 and 53 PWH with early syphilis were randomized to receive CRO/Doxy and BPG/Doxy, respectively. At baseline, 31.2% (n = 34) had chlamydia, 13.8% (n = 15) gonorrhea, and 6.4% (n = 7) Conclusions: In the ITT analysis, CRO/Doxy was not noninferior to BPG/Doxy for early syphilis treatment among PWH at 24 weeks.

Indexed as

chlamydiagonorrheasexually transmitted infectionTreponema pallidum

Identifiers

PMID42614585
PMCPMC13481986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.